Close Menu
Money MechanicsMoney Mechanics
    What's Hot

    How to Strengthen Your Charitable Impact and Legacy

    July 17, 2026

    3 Reasons Why Young People are Filled With Financial Anxiety

    July 17, 2026

    Its Infrastructure Is the AI Investment Nobody Talks About

    July 17, 2026
    Facebook X (Twitter) Instagram
    Trending
    • How to Strengthen Your Charitable Impact and Legacy
    • 3 Reasons Why Young People are Filled With Financial Anxiety
    • Its Infrastructure Is the AI Investment Nobody Talks About
    • Got $2.5 Million Saved? Here Are the Huge RMDs You Must Take
    • Rise of alternative capital in casualty could position legacy market as a pillar of stability: Legacy Roundtable
    • Pending Home Sales Slip
    • Why Rental Property Passive Income Is Harder Today
    • Its Dividend Looks Secure, But Don’t Chase JPM Stock After Q2 Earnings. Here’s Why.
    Facebook X (Twitter) Instagram
    Money MechanicsMoney Mechanics
    • Home
    • Markets
      • Stocks
      • Crypto
      • Bonds
      • Commodities
    • Economy
      • Fed & Rates
      • Housing & Jobs
      • Inflation
    • Earnings
      • Banks
      • Energy
      • Healthcare
      • IPOs
      • Tech
    • Investing
      • ETFs
      • Long-Term
      • Options
    • Finance
      • Budgeting
      • Credit & Debt
      • Real Estate
      • Retirement
      • Taxes
    • Opinion
    • Guides
    • Tools
    • Resources
    Money MechanicsMoney Mechanics
    Home»Markets»Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
    Markets

    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

    Money MechanicsBy Money MechanicsApril 14, 2026No Comments2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Gilead Sciences Inc. (NASDAQ:GILD) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality stocks to buy according to hedge funds. On April 9, Tempus AI (NASDAQ:TEM) announced an expanded, multi-year collaboration with Gilead Sciences to accelerate Gilead’s oncology research and development pipeline. The agreement builds on previous work where Gilead utilized Tempus’ de-identified multimodal data for trial design, biomarker strategies, and health outcomes analysis.

    Under this new enterprise-wide mandate, Gilead gains broader access to Tempus’ AI-driven Lens platform and dedicated analytical services across multiple cancer indications. The partnership aims to use Tempus’ vast library of real-world data to uncover biological insights that can improve clinical decision-making.

    By integrating Gilead’s scientific expertise with advanced data insights, the companies seek to increase the probability of success for new cancer therapies. Patrick Loerch, SVP of Clinical Data Science at Gilead Sciences Inc. (NASDAQ:GILD), emphasized that the collaboration focuses on putting patients at the center of innovation through data-informed research. The collaboration underscores the growing role of AI and real-world evidence in modern drug development and precision medicine.

    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
    Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

    Copyright: dolgachov / 123RF Stock Photo

    Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

    Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

    While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

    Disclosure: None. Follow Insider Monkey on Google News.



    Source link

    AI stock Gilead Sciences multimodal data Tempus AI Tempus AI Inc
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleU.S. natural gas consumption set a monthly and yearly record in 2025
    Next Article Historic Connecticut Mills To Become New Housing After 15-Year Wait
    Money Mechanics
    • Website

    Related Posts

    Rise of alternative capital in casualty could position legacy market as a pillar of stability: Legacy Roundtable

    July 17, 2026

    Its Dividend Looks Secure, But Don’t Chase JPM Stock After Q2 Earnings. Here’s Why.

    July 17, 2026

    What are tank bottoms? – U.S. Energy Information Administration (EIA)

    July 17, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    How to Strengthen Your Charitable Impact and Legacy

    July 17, 2026

    3 Reasons Why Young People are Filled With Financial Anxiety

    July 17, 2026

    Its Infrastructure Is the AI Investment Nobody Talks About

    July 17, 2026

    Got $2.5 Million Saved? Here Are the Huge RMDs You Must Take

    July 17, 2026

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading

    At Money Mechanics, we believe money shouldn’t be confusing. It should be empowering. Whether you’re buried in debt, cautious about investing, or simply overwhelmed by financial jargon—we’re here to guide you every step of the way.

    Facebook X (Twitter) Instagram Pinterest YouTube
    Links
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Resources
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To
    Get Informed

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading
    Copyright© 2025 TheMoneyMechanics All Rights Reserved.
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To

    Type above and press Enter to search. Press Esc to cancel.